A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing—remitting multiple sclerosis (TIME MS)

Opportunistic infections and other risks with newer multiple sclerosis therapies

(2009) Joseph R. Berger et al.   ANNALS OF NEUROLOGY

The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?

(2009) Howard L. Weiner   ANNALS OF NEUROLOGY

Factors that influence adherence with disease-modifying therapy in MS

(2009) Katherine Treadaway et al.   JOURNAL OF NEUROLOGY

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS

(2009) J. A. Cohen et al.   NEUROLOGY

The future of multiple sclerosis therapy☆

(2009) Bernd C. Kieseier et al.   PHARMACOLOGICAL RESEARCH

A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis

(2008) Howard L. Weiner   JOURNAL OF NEUROLOGY

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician

(2008) Aaron Boster et al.   LANCET NEUROLOGY

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

(2008) R. Zivadinov et al.   NEUROLOGY